Skip to main content
Top
Published in: Investigational New Drugs 3/2017

01-06-2017 | SHORT REPORT

Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experience

Published in: Investigational New Drugs | Issue 3/2017

Login to get access

Summary

Background The contents and requirements of study protocols vary depending upon each clinical registration trial. This study aims to describe details of protocol deviations in Japanese oncology registration trials. Methods We reviewed deviation reports that were discussed by the Institutional Review Board between 2010 and 2015. Results A total of 499 clinical trials were performed, from which 967 deviations were reported. In the initial 3 years, 445 deviations occurred in 535 ongoing trials, while 522 deviations occurred in 876 trials in the subsequent 3 years. The frequency of deviations related to visit, examination, treatment, and others was 189 (19.5%), 446 (46.1%), 275 (28.4%), and 57 (5.9%), respectively. Serious deviations were common at the time of registration of trials and during treatment. The deviations were attributable to the institution (n = 520), subject (n = 93), sponsor (n = 28), schedule management (n = 162), disease condition (n = 95), and others (n = 69). Conclusion This study showed the number and detail responsible factors of protocol deviations. Our findings support to distinguish between the measures to reduce the serious deviations and to reduce the overall number of deviations.
Appendix
Available only for authorised users
Literature
1.
go back to reference (ICH) ICoH (1996) ICH harmonised tripartite guideline. Guideline for good clinical practice E6(R1) (ICH) ICoH (1996) ICH harmonised tripartite guideline. Guideline for good clinical practice E6(R1)
2.
go back to reference Welfare MoHa (1997) Ministerial Ordinance. No. 28 (in Japanese) Welfare MoHa (1997) Ministerial Ordinance. No. 28 (in Japanese)
4.
go back to reference Yonemori K, Hirakawa A, Ando M, Hirata T, Shimizu C, Katsumata N, Tamura K, Fujiwara Y (2011) Compliance with good clinical practice in oncology registration trials in Japan. Ann Oncol 22(6):1451–1456. doi:10.1093/annonc/mdq594 CrossRefPubMed Yonemori K, Hirakawa A, Ando M, Hirata T, Shimizu C, Katsumata N, Tamura K, Fujiwara Y (2011) Compliance with good clinical practice in oncology registration trials in Japan. Ann Oncol 22(6):1451–1456. doi:10.​1093/​annonc/​mdq594 CrossRefPubMed
5.
go back to reference Saito K, Kodama Y, Ono S, Maida C, Fujimura A, Miyamoto E (2008) Reliability of Japanese clinical trials estimated from GCP audit findings. Int J Clin Pharmacol Ther 46(8):415–420CrossRefPubMed Saito K, Kodama Y, Ono S, Maida C, Fujimura A, Miyamoto E (2008) Reliability of Japanese clinical trials estimated from GCP audit findings. Int J Clin Pharmacol Ther 46(8):415–420CrossRefPubMed
6.
go back to reference Saito K, Kodama Y, Ono S, Mutoh M, Kawashima S, Fujimura A (2006) Quality of Japanese clinical trials estimated from good clinical practice audit findings. Am J Ther 13(2):127–133CrossRefPubMed Saito K, Kodama Y, Ono S, Mutoh M, Kawashima S, Fujimura A (2006) Quality of Japanese clinical trials estimated from good clinical practice audit findings. Am J Ther 13(2):127–133CrossRefPubMed
9.
go back to reference Ono S, Kodama Y, Nagao T, Toyoshima S (2002) The quality of conduct in Japanese clinical trials: deficiencies found in GCP inspections. Control Clin Trials 23(1):29–41CrossRefPubMed Ono S, Kodama Y, Nagao T, Toyoshima S (2002) The quality of conduct in Japanese clinical trials: deficiencies found in GCP inspections. Control Clin Trials 23(1):29–41CrossRefPubMed
11.
go back to reference Akiyama T, Furuta M, Yamada H (2006) In order to perform clinical trials efficiently in Japan. Ann Jpn Respir Soc 44(8):541–549 Akiyama T, Furuta M, Yamada H (2006) In order to perform clinical trials efficiently in Japan. Ann Jpn Respir Soc 44(8):541–549
12.
go back to reference Kaichi S, Oda T, Goto K, Sato K (2007) In order to perform clinical trials efficiently in Japan: important issues regarding monitoring by sponsors. Ann Jpn Respir Soc 45(11):829–835 Kaichi S, Oda T, Goto K, Sato K (2007) In order to perform clinical trials efficiently in Japan: important issues regarding monitoring by sponsors. Ann Jpn Respir Soc 45(11):829–835
13.
go back to reference Nakahama Y, Terakado H, Fujiwara Y (2012) New trend for global clinical development. J Clin Ther Med 28(3):205–209 Nakahama Y, Terakado H, Fujiwara Y (2012) New trend for global clinical development. J Clin Ther Med 28(3):205–209
14.
go back to reference Fujiwara Y (2007) Infrastructure development and human resources training for clinical trials. The national cancer center hospital as an example. Pharm Regul Sci 38:646–650 Fujiwara Y (2007) Infrastructure development and human resources training for clinical trials. The national cancer center hospital as an example. Pharm Regul Sci 38:646–650
15.
go back to reference America IoMUCoQoHCi (2000) To Err Is Human: Building a Safer Health System. The National Academies Press, Washington, DC. doi:10.17226/9728 America IoMUCoQoHCi (2000) To Err Is Human: Building a Safer Health System. The National Academies Press, Washington, DC. doi:10.​17226/​9728
Metadata
Title
Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experience
Publication date
01-06-2017
Published in
Investigational New Drugs / Issue 3/2017
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-017-0434-3

Other articles of this Issue 3/2017

Investigational New Drugs 3/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine